AssetMark Inc
CPRX

AssetMark Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

AssetMark Inc’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.88M Buy
123,492
+21,056
+21% +$621K 0.01% 804
2026
Q1 		$2.54M Buy
102,436
+16,299
+19% +$388K 0.01% 827
2025
Q4 		$2.01M Sell
86,137
-3,172
-4% -$70.7K ﹤0.01% 852
2025
Q3 		$1.76M Buy
89,309
+12,669
+17% +$261K ﹤0.01% 851
2025
Q2 		$1.66M Sell
76,640
-6,596
-8% -$156K ﹤0.01% 807
2025
Q1 		$2.02M Buy
83,236
+12,434
+18% +$280K 0.01% 721
2024
Q4 		$1.48M Sell
70,802
-1,443
-2% -$31K ﹤0.01% 775
2024
Q3 		$1.44M Buy
72,245
+1,704
+2% +$31.6K ﹤0.01% 718
2024
Q2 		$1.09M Buy
70,541
+1,866
+3% +$29.1K ﹤0.01% 743
2024
Q1 		$1.09M Buy
68,675
+3,997
+6% +$60.2K ﹤0.01% 713
2023
Q4 		$1.09M Buy
64,678
+2,505
+4% +$34.2K ﹤0.01% 660
2023
Q3 		$727K Buy
62,173
+6,218
+11% +$83.2K ﹤0.01% 685
2023
Q2 		$752K Sell
55,955
-2,093
-4% -$30.1K ﹤0.01% 654
2023
Q1 		$962K Buy
58,048
+566
+1% +$9.34K ﹤0.01% 606
2022
Q4 		$1.07M Sell
57,482
-1,650
-3% -$25.4K ﹤0.01% 555
2022
Q3 		$759K Buy
+59,132
New +$701K ﹤0.01% 578

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AssetMark Inc's CPRX Position: Q2 2026 in Review

AssetMark Inc increased its Catalyst Pharmaceutical (CPRX) stake by 21% in Q2 2026, buying an estimated $621K and bringing the position to 123,492 shares worth $3.88M. The position accounts for 0.01% of the portfolio, ranked #804.

AssetMark Inc first reported a position in CPRX in Q3 2022 and has held it in 16 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • AssetMark Inc held 123,492 shares of Catalyst Pharmaceutical worth $3.88M as of Q2 2026.
  • AssetMark Inc bought 21,056 Catalyst Pharmaceutical shares in Q2 2026, an estimated $621K.
  • Catalyst Pharmaceutical made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #804 holding.
  • AssetMark Inc first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.